Journal of Hepatology最新文献

{"title":"Revealing Bias in Feature Importance through PLS-DA: A Critical Examination of Machine Learning Applications in Chronic Liver Disease.","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.jhep.2024.12.021","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.021","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":26.8,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The HDL criterion for MetALD can misclassify patients with cirrhosis","authors":"Gene Y. Im, Ashish Bibireddy, Smruti Rath","doi":"10.1016/j.jhep.2024.12.026","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.026","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>GI: Study concept, data collection, data analysis, manuscript writingAB: Data collectionSR: Study concept, data collection, data analysis, manuscript writing</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>NonePlease refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>None</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"19 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitions in the nomenclatures for fatty liver disease","authors":"Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George","doi":"10.1016/j.jhep.2024.12.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.019","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Clinical trial number:</h2>Not applicable.</section></section><section><section><h2>Authors’ contributions</h2>The conception, data collection, and drafting the manuscript were performed by MS and ME. All authors critically reviewed, revised, and approved the final manuscript.</section></section><section><section><h2>Data availability statement</h2>The R code for the analysis was deposited in GitHub (<span><span>https://github.com/maitosuoh/fatty-liver-time-series</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>).</section></section><section><section><h2>Financial support</h2>SE, ME, and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, The University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206), Project, Ideas and Investigator Grants (APP2001692, GNT1107178, GNT1108422, GNT1196492, GNT2008983) and a Cancer Institute, NSW grant (2021/ATRG2028).</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare that they have no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>Not applicable.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"52 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","authors":"","doi":"10.1016/j.jhep.2024.08.028","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.08.028","url":null,"abstract":"Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers. Advances in diagnostic and therapeutic tools, along with improved understanding of their application, are transforming patient treatment. Integrating these innovations into clinical practice presents challenges and necessitates guidance. These clinical practice guidelines offer updated advice for managing patients with HCC and provide a comprehensive review of pertinent data. Key updates from the 2018 EASL guidelines include personalised surveillance based on individual risk assessment and the use of new tools, standardisation of liver imaging procedures and diagnostic criteria, use of minimally invasive surgery in complex cases together with updates on the integrated role of liver transplantation, transitions between surgical, locoregional, and systemic therapies, the role of radiation therapies, and the use of combination immunotherapies at various stages of disease. Above all, there is an absolute need for a multiparametric assessment of individual risks and benefits, considering the patient's perspective, by a multidisciplinary team encompassing various specialties.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"8 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research","authors":"Chenxi Wang, Huichuan Tian, Jin Shang","doi":"10.1016/j.jhep.2024.12.023","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.023","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Chenxi Wang designed this project and wrote the manuscript. Jin Shang collected the data. Huichuan Tian contributed to reviewing and editing the paper. All authors read and approved the final manuscript.</section></section><section><section><h2>Financial support</h2>No funding was received to assist with the preparation of this manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>Not applicable.</section></section><section><section><h2>Acknowledgements</h2>Not applicable.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: A Sensitivity Analysis Quantifying Effect of Unmeasured Confounding factors on Observational Associations","authors":"Guiying Gao, Jie Guo, Guo Yu, Guo-Fu Li","doi":"10.1016/j.jhep.2024.12.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Guo-Fu Li concepted and designed the study, analyzed and interpreted the data, and drafted the manuscript. Guiying Gao and Jie Guo contributed to the data collection and analysis. Guo Yu and Guo-Fu Li supervised the study and revised the manuscript. Guo Yu administered the study. All authors reviewed and approved the final manuscript.</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>The data can be available by reasonable request from the corresponding author.</section></section><section><section><h2>Financial support</h2>Guo Yu reports receiving grants from Jiangsu Provincial Natural Science Fund for Distinguished Young Scholars (BK20200005).</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare no conflicts of interest that pertain to this work.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>The anonymous reviewer #3 added much to this manuscript.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EASL Congress 2025: prepare and submit your late-breaker!","authors":"","doi":"10.1016/s0168-8278(24)02671-0","DOIUrl":"https://doi.org/10.1016/s0168-8278(24)02671-0","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"47 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rifaximin in cirrhosis: Is its microbiological spotless record under threat?","authors":"Cornelius Engelmann","doi":"10.1016/j.jhep.2024.11.033","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.033","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Patients with cirrhosis are particularly vulnerable to infections and other complications due to immune dysfunction and intestinal barrier impairment, leading to frequent antibiotic use and an associated rise in multidrug-resistant (MDR) organisms in this population.[1], [2], [3] Among the antimicrobials frequently employed, rifaximin, a gut-specific antibiotic with minimal systemic absorption, has gained prominence for the prevention of recurrent hepatic encephalopathy (HE).[4], [5], [6] Its</section></section><section><section><h2>Objectives, methods, and findings</h2>The recently published study in <em>Nature</em> by Turner <em>et al.</em>¹³ primarily aimed to uncover the mechanisms driving daptomycin resistance in vancomycin-resistant <em>Enterococcus faecium</em> (VREfm), focusing on unexplored genomic and phenotypic factors. Researchers analyzed a collection of 717 VREfm isolates from Australia, where they observed that 19.4% of the strains exhibited daptomycin resistance. To identify resistance mechanisms, the team screened the genomes of DAP-resistant and susceptible strains.</section></section><section><section><h2>Significance of findings</h2>This study highlights an emerging issue at the intersection of rifaximin use and the development of cross-resistance to a last resort antibiotic in VREfm via rpoB mutations. The findings present compelling experimental evidence about the potential mechanism but also raise significant unanswered questions, emphasizing the need for a nuanced evaluation of clinical implications and future directions in research.The association between rifaximin exposure and rpoB-mediated daptomycin resistance is</section></section><section><section><h2>Financial support</h2>The author did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Conflict of interest</h2>The author of this study declares that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure form for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"16 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Register now for the EASL SLD Summit 2025, 23-25 January in Estoril","authors":"","doi":"10.1016/s0168-8278(24)02672-2","DOIUrl":"https://doi.org/10.1016/s0168-8278(24)02672-2","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"38 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden metabolic effects of acetyl-CoA carboxylase inhibition","authors":"Panu K. Luukkonen","doi":"10.1016/j.jhep.2024.11.043","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.043","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one-third of the global population, yet effective therapeutic options remain limited.¹ This unmet clinical need has driven significant interest in the development of pharmacological therapies for MASLD, including small-molecule inhibitors targeting acetyl-CoA carboxylase (ACC). These inhibitors have demonstrated potential in preclinical studies by reducing hepatic lipid accumulation and fibrosis.²^,³ACC, a key enzyme</section></section><section><section><h2>Objectives, methods, and findings</h2>Deja <em>et al.</em> hypothesized that malonyl-CoA may have broader metabolic roles beyond its established functions in fatty acid synthesis and oxidation. Specifically, they proposed that it may regulate gluconeogenesis by influencing metabolic substrates and enzymatic pathways. Using liver-specific genetic and pharmacological approaches, combined with targeted metabolomics and stable isotope tracing, the authors systematically explored the effects of ACC1/2 inhibition on hepatic metabolism.Their</section></section><section><section><h2>Significance of findings</h2>Taken together, the findings by Deja <em>et al.</em> provide critical new insights into the multifaceted roles of ACC inhibition in hepatic metabolism. Beyond its established effects on DNL and β-oxidation, the authors clearly demonstrated that ACC also acts as a key regulator of gluconeogenesis, mediating its effects via acetyl-CoA activation of pyruvate carboxylase and increased availability of gluconeogenic substrates through intrahepatic proteolysis.This study raises several important questions for</section></section><section><section><h2>Financial support</h2>Dr. Luukkonen was supported by the <span>Academy of Finland</span> (<span>350545</span>), the Sigrid Jusélius Foundation, the <span>Novo Nordisk Foundation</span> (<span>NNF22OC0074397</span>), the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Wilhelm and Else Stockmann's Foundation and the Early Career Investigator fund of the University of Helsinki.</section></section><section><section><h2>Declaration of AI-assisted technologies in the writing process</h2>During the preparation of this work the author used ChatGPT in order to proofread the manuscript. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the publication.</section></section><section><section><h2>Conflict of interest</h2>The author has served as a consultant for AstraZeneca, Boehringer Ingelheim and Bluejay Therapeutics. He is on the speakers' bureau for Novartis, Johnson &amp; Johnson and Sandoz.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"50 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}